Nystatin-Triamcinolone (nystatin/triamcinolone acetonide)

Dosage of nystatin is expressed in terms of USP nystatin units.

Dermatologic preparations of triamcinolone acetonide are applied sparingly in thin films and are rubbed gently into the affected area 2-4 times daily. The 0.5% cream and 0.5% ointment should be used only in the treatment of dermatoses which are refractory to treatment with lower concentrations. The 0.1 and 0.5% creams are applied 2-3 times daily according to severity of the condition. When the aerosol is applied, an area about the size of the patient's hand is sprayed for about 2 seconds from a distance of about 7.5-15 cm 3 or 4 times daily. Occlusive dressings may be used for severe or resistant dermatoses.

For use in the mouth, a small amount (about 0.6 cm) of the 0.1% paste is pressed to the lesion without rubbing until a thin film develops; a larger amount may be required to cover some lesions. The paste is applied at bedtime and, if necessary, 2 or 3 times daily, preferably after meals. If substantial regeneration or repair of the oral tissues does not occur after 7 days of treatment, further investigation of the etiology of the oral lesions should be undertaken.

Nystatin is applied topically to the skin as a cream, ointment, or powder. Nystatin also is commercially available in fixed combination with a corticosteroid (i.e., triamcinolone acetonide) for topical application to the skin as a cream or ointment.

Nystatin is applied topically to the oral cavity as an oral suspension and is administered orally as film-coated tablets.

Although nystatin has been administered intravaginally, intravaginal preparations of the drug are no longer commercially available in the US.

No dosing information is available for this tab.

No dosing information is available for this tab.

There is no enhanced messaging for this drug.

There are no contraindication interactions for this drug.

There are no severe interactions for this drug.

There are no moderate interactions for this drug.

There is no enhanced messaging for this drug.

There are no contraindication contraindications for this drug.

There are no severe contraindications for this drug.

There are no moderate contraindications for this drug.

There is no enhanced messaging for this drug.

There are no severe adverse reactions for this drug.

There are no less severe adverse reactions for this drug.

No enhanced messaging available.

No enhanced messaging available.

Animal reproduction studies have not been performed using topical or oral nystatin. It is not known whether nystatin can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity.

Topical nystatin should be used during pregnancy only if potential benefits outweigh potential risks to the fetus.

Oral nystatin (oral suspension, tablets) should be used during pregnancy only if clearly needed.

Fixed-combination topical preparations containing nystatin and triamcinolone acetonide should be used during pregnancy only if potential benefits outweigh potential risks to the fetus. Topical preparations containing corticosteroids should not be used extensively, in large amounts, or for prolonged periods during pregnancy.

It is not known whether nystatin is distributed into human milk.

Nystatin and fixed combinations containing nystatin and triamcinolone acetonide should be used with caution in nursing women.

No enhanced messaging available.